2024 was pivotal for TCR therapies. Following the commercial approval for Adaptimmune’s Tecelra, positive clinical readouts, and FIH trials from Immatics, Triumvira, Affini-T, CDR-Life, and TScan, along with a wealth of investment and partnerships amounting to over $700M, it’s time to come together to relish in these breakthroughs, while pouring this energy into expanding TCR treatment potential. 

The 6th TCR-Based Therapies Summit returned as the only TCR-specific platform for industry experts to join forces to share the technical insights to transform discovery, translation, R&D, and clinical development for cell- and biologic-based approaches.

We provided an unmatched close-knit collaboration environment created specifically with and for the TCR community to connect and learn from leaders such as Immunocore, Immatics, Marengo, TScan, Medigene, and BioNTech, in a bid to validate novel target antigens, discover safe, potent and optimized TCRs, boost durability in the solid TME, and delve into clinical data, to deliver to more patient populations and achieve clinical validation.